HomeAI · summaries
Storia in 3 fonti
Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue
Dr. Reddy’s Q1 net profit drops 69% to ₹435.6 crore due to lower lenalidomide sales and semaglutide quality issues.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Q1 FY27 preview: Dr Reddy’s likely to face pressure on earnings
Dr Reddy's FY27 Q1 preview indicates potential earnings pressure, with analysts predicting significant declines in profit and EBITDA.
- ·
Dr Reddy's Q1 profit falls 69% to ₹434 crore as lenalidomide transition weighs
Dr Reddy's Laboratories reported a 69% fall in Q1 profit to ₹434 crore as lenalidomide transition and semaglutide API impact offset base business growth.
- ·
thehindu.com
Dr. Reddy’s Q1 net plunges 69% to ₹435.6 cr on lower revenue
Dr. Reddy’s Q1 net profit drops 69% to ₹435.6 crore due to lower lenalidomide sales and semaglutide quality issues.
- ·
economictimes.indiatimes.com
Dr Reddy’s aims to resume semaglutide supply by November after API fix
Dr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and plans corrective measures by September.…